PMID- 17385944
OWN - NLM
STAT- MEDLINE
DCOM- 20070705
LR  - 20181113
IS  - 0012-6667 (Print)
IS  - 0012-6667 (Linking)
VI  - 67
IP  - 5
DP  - 2007
TI  - Sitaxentan: in pulmonary arterial hypertension.
PG  - 761-70; discussion 771-2
AB  - Sitaxentan is a highly selective endothelin (ET)(A) receptor antagonist, with an 
      approximately 6500 higher affinity for ET(A) than ET(B) receptors. In pulmonary 
      arterial hypertension (PAH), elevated ET-1 levels are strongly correlated with 
      disease severity and prognosis. Sitaxentan 100 mg once daily was efficacious in 
      the management of moderate to severe PAH in the pivotal, 12-18 week, large (n > 
      or = 98), well designed, placebo-controlled STRIDE-1, -2 and -4 trials. In the 
      STRIDE-1 and -2 trials (the majority of patients had New York Heart Association 
      [NYHA]/WHO functional class III PAH), sitaxentan-treated patients experienced 
      significantly greater improvements from baseline in distance walked over 6 
      minutes (6MWD; primary endpoint in STRIDE-2) and in NYHA/WHO functional class 
      than placebo recipients. In STRIDE-4, although there was no between-group 
      difference in terms of improvements in 6MWD in the primary analysis of patients 
      across all WHO functional classes (61% were functional class II) [primary 
      endpoint], improvements in 6MWD significantly favoured sitaxentan versus 
      placebo-treated patients in a post hoc subgroup analysis of those with WHO 
      functional class III or IV disease. The beneficial effects of sitaxentan therapy 
      on exercise capacity and NYHA/WHO functional class were maintained after up to 2 
      years' treatment. Treatment with sitaxentan for up to 2 years was generally well 
      tolerated in clinical trials.
FAU - Scott, Lesley J
AU  - Scott LJ
AD  - Wolters Kluwer Health/ Adis, Auckland, New Zealand. demail@adis.co.nz
LA  - eng
PT  - Journal Article
PT  - Review
PL  - New Zealand
TA  - Drugs
JT  - Drugs
JID - 7600076
RN  - 0 (Endothelin A Receptor Antagonists)
RN  - 0 (Isoxazoles)
RN  - 0 (Receptor, Endothelin A)
RN  - 0 (Thiophenes)
RN  - J9QH779MEM (sitaxsentan)
SB  - IM
MH  - *Endothelin A Receptor Antagonists
MH  - Humans
MH  - Hypertension, Pulmonary/*drug therapy/metabolism
MH  - Isoxazoles/administration & dosage/*therapeutic use
MH  - Randomized Controlled Trials as Topic
MH  - Receptor, Endothelin A/metabolism
MH  - Thiophenes/administration & dosage/*therapeutic use
MH  - Treatment Outcome
RF  - 34
EDAT- 2007/03/28 09:00
MHDA- 2007/07/06 09:00
CRDT- 2007/03/28 09:00
PHST- 2007/03/28 09:00 [pubmed]
PHST- 2007/07/06 09:00 [medline]
PHST- 2007/03/28 09:00 [entrez]
AID - 6757 [pii]
AID - 10.2165/00003495-200767050-00007 [doi]
PST - ppublish
SO  - Drugs. 2007;67(5):761-70; discussion 771-2. doi: 
      10.2165/00003495-200767050-00007.